Estimaciones de analistas de Wall Street para CNS Pharmaceuticals, Inc. (CNSP): precio objetivo de consenso, recomendaciones de compra/mantener/venta y previsiones de ingresos, BPA y EBITDA para los próximos ejercicios.
Consenso de analistas
| Compra fuerte | 0 |
| Compra | 4 |
| Mantener | 0 |
| Venta | 0 |
| Venta fuerte | 0 |
| Analistas totales | 4 |
| Calificación media (1-5) | 1.00 |
Sorpresas de Resultados Recientes
| Fecha | BPA Real | BPA Estimado | vs Est. |
|---|---|---|---|
| 2026-11-18 | $-0.27 | ||
| 2026-08-12 | $-0.38 | $-0.24 | -58.3% |
| 2026-05-14 | $-7.30 | $-5.37 | -35.9% |
| 2026-03-31 | $-5.09 | $-5.09 | +0.0% |
| 2025-11-14 | $-5.76 | $-6.63 | +13.1% |
| 2025-08-14 | $-6.42 | $-9.60 | +33.1% |
| 2025-05-15 | $-18.97 | $-24.00 | +21.0% |
| 2025-03-31 | $-447.96 | $-87.96 | -409.3% |
Ratios de valoración
| Precio / Valor contable | 2.01 |
| EV / EBITDA | 0.70 |
| Rentabilidad por dividendo | 0.00% |
Cuenta de Resultados (10 años)
| Año | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Ingresos | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Coste de Ventas | 0 | 0 | $1955 | $11096 | $13070 | $11756 | $4134 | $3306 | 0 |
| Beneficio Bruto | 0 | 0 | -$1955 | -$11096 | -$13070 | -$11756 | -$4134 | -$3306 | 0 |
| I+D | $32638 | $21267 | $1.9M | $5.1M | $9.8M | $9.3M | $14.1M | $9.3M | $9.8M |
| Generales y Administrativos | $182467 | $860520 | $2.0M | $4.4M | $4.7M | $5.6M | $4.8M | $5.6M | $6.2M |
| Gastos Operativos | $215105 | $881787 | $3.8M | $9.4M | $14.5M | $14.9M | $18.9M | $14.9M | $16.0M |
| Beneficio Operativo | -$516252 | -$881787 | -$3.8M | -$9.5M | -$14.5M | -$14.9M | -$18.9M | -$14.9M | -$16.0M |
| EBITDA | 0 | -$6.5M | -$3.8M | -$9.4M | -$14.5M | -$15.3M | -$18.8M | -$14.8M | -$15.8M |
| Gastos por Intereses | $4257 | $46697 | $44234 | $3264 | $9285 | $7027 | $13805 | $16119 | $15230 |
| Beneficio Antes de Impuestos | -$219362 | -$7.4M | -$3.9M | -$9.5M | -$14.5M | -$15.3M | -$18.9M | -$14.9M | -$15.9M |
| Impuestos | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Neto | -$526469 | -$7.4M | -$3.9M | -$9.5M | -$14.5M | -$15.3M | -$18.9M | -$14.9M | -$15.9M |
| BPA | $-11997.00 | $-404415.00 | $-212121.00 | $-512208.00 | $-495027.00 | $-336499.00 | $-150114.00 | $-466.44 | $-35.75 |
| BPA Diluido | $-11997.00 | $-404415.00 | $-212121.00 | $-512208.00 | $-495027.00 | $-336499.00 | $-150114.00 | $-466.44 | $-35.75 |
| Acciones en Circulación (Diluidas) | $18 | $18 | $18 | $18 | $29 | $45 | $126 | $31853 | $443369 |
Precio
| Precio | $5.50 |
| Capitalización | $8M |
| Bolsa | NASDAQ |
| País | US |
Empresas relacionadas: CMND · ENSC · GRI · KTTA · NLSP · OGEN · SILO
Explorar sector: Healthcare · Biotechnology
Más secciones de CNSP: Resumen · Financieros · Valoración · Estadísticas · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones